ReviewEmerging microbes & infections2018
The disparate effects of bacteriophages on antibiotic-resistant bacteria.
Review in Emerging microbes & infections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 188 citations in OpenAlex.
- Acid-Mediated Antimicrobial Activity and Probiotic Potential of an SKS1-knockout Saccharomyces Cerevisiae Strain.Probiotics and antimicrobial proteins · 2026Article
- Short-Term Bacteriophage Exposure Is Associated with Shifts in Antibiotic Susceptibility Profiles of ClinicalMicroorganisms · 2026Article
- Unveiling the viral dimension: The paediatric gut virome as a key modulator of gastrointestinal metabolic, and neurodevelopmental health.World journal of virology · 2026Review
- Characterization of broad-host-range bacteriophages targeting multidrug-resistant E. coli and Shigella spp.: in vitro potential.BMC microbiology · 2026Article
- Host-pathogen interactions in periodontitis: an integrative interkingdom perspective.Frontiers in immunology · 2026Review
- Three Novel Bacteriophages for the Biocontrol ofPathogens (Basel, Switzerland) · 2025Article
- Next-generation antimicrobials: A review of phage lysins as precision weapons against drug-resistant pathogens.Virulence · 2025Review
- Unveiling the Mechanisms of Bacterial Resistance and Countermeasures.Pathogens (Basel, Switzerland) · 2025Review
- Evolutionary selection of trimethoprim-resistantScience advances · 2025Article
- From Microbial Consortia to Ecosystem Resilience: The Integrative Roles of Holobionts in Stress Biology.Biology · 2025Article
- Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Phage Therapy in Managing Multidrug-Resistant (MDR) Infections in Cancer Therapy: Innovations, Complications, and Future Directions.Pharmaceutics · 2025Review
- Phage treatment of multidrug-resistant bacterial infections in humans, animals, and plants: The current status and future prospects.Infectious medicine · 2025Review
- Development of a novel chimeric lysin to combine parental phage lysin and cefquinome for preventing sow endometritis after artificial insemination.Veterinary research · 2025Article
- Genomic insights into bacteriophages: a new frontier in AMR detection and phage therapy.Briefings in functional genomics · 2025Review
- Exploration of bacteriophage therapy as a viable alternative to combat antibiotic-resistant bacterial infections: A comprehensiveBioinformation · 2025Article
- An insight into the applications of bacteriophages against food-borne pathogens.Journal of food science and technology · 2025Review
- The gut and circulating virome: emerging players in aging and longevity.Frontiers in aging · 2025Review
- Therapeutic Phage Candidates for Targeting Prevalent Sequence Types of Carbapenem-ResistantFoodborne pathogens and disease · 2024Article
- The potential use of bacteriophages as antibacterial agents in dental infection.Virology journal · 2024Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Faced with the crisis of multidrug-resistant bacteria, bacteriophages, viruses that infect and replicate within bacteria, have been reported to have both beneficial and detrimental effects with respect to disease management. Bacteriophages (phages) have important ecological and evolutionary impacts on their bacterial hosts and have been associated with therapeutic use to kill bacterial pathogens, but can lead to the transmission of antibiotic resistance. Although the process known as transduction has been reported for many bacterial species by classic and modern genetic approaches, its contribution to the spread of antibiotic resistance in nature remains unclear. In addition, detailed molecular studies have identified phages residing in bacterial genomes, revealing unexpected interactions between phages and their bacterial hosts. Importantly, antibiotics can induce the production of phages and phage-encoded products, disseminating these viruses and virulence-related genes, which have dangerous consequences for disease severity. These unwanted side-effects of antibiotics cast doubt on the suitability of some antimicrobial treatments and may require new strategies to prevent and limit the selection for virulence. Foremost among these treatments is phage therapy, which could be used to treat many bacterial infectious diseases and confront the pressing problem of antibiotic resistance in pathogenic bacteria. This review discusses the interactions between bacteriophages, antibiotics, and bacteria and provides an integrated perspective that aims to inspire the development of successful antibacterial therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.